Summary of Original Version

Amend KRS 304.17A-611 to prohibit insurers from requiring or using certain utilization reviews for certain prescription drugs used to treat alcohol or opioid use disorder; amend KRS 205.536 to prohibit the Department for Medicaid Services or a Medicaid managed care organization from requiring or using certain utilization reviews for certain prescription drugs used to treat alcohol or opioid use disorder; create a new section of Subtitle 17A of KRS Chapter 304 to require insurers to report the number and type of providers prescribing medication for addiction treatment; require the Department of Insurance to report to the General Assembly and State Board of Medical Licensure; EFFECTIVE in part January 1, 2022.

Summary of Amendment: Senate Committee Substitute 1

Summary Retain original provisions; except amend KRS 304.17A-611 and KRS 205.536 to prohibit concurrent and prospective utilization review of prescription drugs that are FDA-approved for the mitigation of opioid withdrawal; require the Department of Insurance to report to the Kentucky Board of Nursing; create a new section of KRS Chapter 222 to require a treating facility to submit a written discharge plan to the patient and the patient's third-party payor.

Summary of Amendment: House Floor Amendment 1 -- K. Moser

Summary Retain original provisions except amend Section 2 to insert conforming language; amend Sections 1 and 2 to limit requirements for prescription drugs approved for the mitigation of opioid withdrawal symptoms; and require the Cabinet for Health and Family Services or the Department for Medicaid Services to apply for a waiver or authorization and report to the co-chairs and Interim Joint Committee on Health, Welfare, and Family services if certain conditions are met.

Statutes affected:
Introduced: 205.536, 205.522
Acts Chapter 201: 205.536, 205.522
Senate Committee Substitute 1: 205.536, 205.522
Current: 205.536, 205.522